Enclomiphene Citrate

Overview

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM). It is most often discussed as an ancillary compound for men with secondary hypogonadism — low testosterone driven by insufficient signaling from the brain rather than by a problem in the testes themselves.

Its main point of interest is that, in studies, it raised the body’s own testosterone by stimulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH), rather than replacing testosterone from an outside source. This mechanism is associated with preserved sperm production, which is why it is often contrasted with conventional testosterone therapy.

Enclomiphene is favored by some over clomiphene because it lacks zuclomiphene, the longer-lived estrogenic isomer present in clomiphene. Despite reaching late-stage clinical trials under the name Androxal, it was never approved as a marketed drug, and it is sold for research purposes only.

How it works

Enclomiphene acts as an estrogen receptor antagonist at the hypothalamus and pituitary. By blocking estrogen’s negative feedback there, it prompts increased release of the gonadotropins LH and FSH, which in turn signal the testes to produce more testosterone and to maintain spermatogenesis.

Because it works upstream on the hypothalamic-pituitary-gonadal axis rather than supplying testosterone directly, the studied effect is a restorative one — raising endogenous hormone output while, in the reported trials, conserving semen parameters. The precise long-term effects in humans are still being characterized.

Reported benefits

• Raised endogenous testosterone in men with secondary hypogonadism (clinical trial data)
• Increases in LH and FSH, consistent with restored HPG-axis signaling
• Preservation of sperm production, in contrast to exogenous testosterone
• Fewer estrogenic effects than clomiphene, attributed to the absence of zuclomiphene

These are reported and studied effects, not guaranteed outcomes.

Considerations & side effects

Enclomiphene reached phase III trials but was not approved, and long-term safety data outside of those studies is limited. Reported side effects in trials were generally mild and included headache, nausea, and changes in mood; as a compound that shifts estrogen signaling, effects such as hot flashes or visual disturbances associated with the SERM class are also relevant considerations.

Product purity varies widely in the research-chemical market, and material sold as enclomiphene may differ from the compound studied in trials. It is not a substitute for evaluation and treatment by a qualified clinician.